Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However, they aren’t giving up on the pathway targeted by the molecule -- phosphoinositide 3-kinase (PI3K).

The double-blind, international SANDPIPER

Read the full 533 word article

User Sign In